Soleno Therapeutics (SLNO) Assets (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Assets data on file, last reported at $608.4 million in Q1 2026.

• On a quarterly basis, Assets rose 91.26% year-over-year to $608.4 million in Q1 2026; TTM through Mar 2026 was $608.4 million, a 91.26% increase from a year earlier, with the FY2025 full-year figure at $563.8 million, up 70.36% from the prior year.
• Assets for Q1 2026 stood at $608.4 million, up from $563.8 million in the prior quarter.
• Over the last five years, Assets for SLNO reached as high as $608.4 million in Q1 2026 and fell as low as $19.5 million in Q1 2023.
• Historically, Assets has averaged $232.7 million across 5 years, with a median of $180.7 million in 2023.
• Across the five-year window, Assets plunged 54.08% in 2023 and jumped 882.84% in 2024, its largest moves.
• Year by year, Assets stood at $26.5 million in 2022, then soared by 581.93% to $180.7 million in 2023, then surged by 83.17% to $331.0 million in 2024, then soared by 70.36% to $563.8 million in 2025, then grew by 7.9% to $608.4 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $608.4 million in Q1 2026, $563.8 million in Q4 2025, and $599.9 million in Q3 2025.